Login
$AVIR
$4.25 -$0.05 (1.28%) Live

$AVIR 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection

09 Nov 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

CERTAIN INFORMATION MARKED AS [* * *] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.

12 Aug 2026 8-K: Results of Operations and Financial Condition

Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV

22 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2026, Atea Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 59,742,819 shares of the Company’s common stock were present in person or represented...

12 May 2026 8-K: Results of Operations and Financial Condition

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on

05 Mar 2026 8-K: Results of Operations and Financial Condition

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-En...

08 Jan 2026 8-K: Results of Operations and Financial Condition

Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026

12 Nov 2025 8-K: Results of Operations and Financial Condition

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026

07 Aug 2025 8-K: Results of Operations and Financial Condition

Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV

20 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 20, 2025, Atea Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 74,981,407 shares of the Company’s common stock were present in person or represented...

12 May 2025 8-K: Results of Operations and Financial Condition

Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV

17 Apr 2025 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

This letter (this “Agreement”) constitutes an agreement by and among (a) Atea Pharmaceuticals, Inc. (the “Company”) and (b) Bradley L. Radoff (and together with The Radoff Family Foundation, “Radoff”) and JEC II Associates, LLC (and toge...

01 Apr 2025 8-K: Other Events

On March 31, 2025, Atea Pharmaceuticals, Inc. (the “Company” or “Atea”) received notice from Driver Opportunity Partners III withdrawing its prior notice that it intended to nominate J. Abbott R. Cooper to stand for election to the Compa...

24 Mar 2025 8-K: Other Events

BOSTON, March 21, 2025 (5:54 PM ET) (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for ser...

06 Mar 2025 8-K: Results of Operations and Financial Condition

Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV)

24 Feb 2025 8-K: Departure/Election of Directors or Officers; Compensation

On February 20, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) elected Arthur Kirsch as a Class I director of the Company, effective immediately.

14 Jan 2025 8-K: Results of Operations and Financial Condition

Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approximately $3 Billion in Annual Net Sales

07 Nov 2024 8-K: Results of Operations and Financial Condition

Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4’24

07 Aug 2024 8-K: Results of Operations and Financial Condition

Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete

21 Jun 2024 8-K: Submission of Matters to a Vote of Security Holders

On June 21, 2024, Atea Pharmaceuticals, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). Holders of a total of 74,365,479 shares of common stock were present in person or represented by proxy at t...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support